Methamphetamine Addiction

Year 2022, , 98 - 101, 29.10.2022

Bilge İvecen , Ozden Gokdemır

https://doi.org/10.56016/dahudermj.1184367

Cited By: 1

Abstract

A person can develop addiction to many kinds of substances. Methamphetamine is the second most widely abused drug worldwide. Long-term methamphetamine usage may cause social, psychological, and physical problems. Long-term effects (such as weight loss, memory loss, tremors, convulsion, psychosis, paranoia, hallucinations, Parkinson's-like symptoms, and cardiovascular collapse) and short-term effects (such as euphoria, dilated pupils, insomnia, reduced appetite, increased blood pressure ) are listed and, brain damage and mental problems due to methamphetamine abuse are briefly mentioned in this text. The severity of withdrawal symptoms varies from person to person. Unfortunately, there is no exact cure for methamphetamine abuse. This is not a systematic review.

Keywords

methamphetamine, addiction, brain damage, meth mouth

Supporting Institution

None

Project Number

None

References

• https://www.psychiatry.org/patients-families/addiction/what-is-addiction
• Anglin MD, Burke C, Perrochet B, et al. History of the methamphetamine problem. J Psychoactive Drugs 2000;32:137-41. [PubMed]
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxitene treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901.
• Frese PA, McClure E. Methamphetamine: Implications for the dental team. Proctor & Gamble. Accessed March 18, 2019.
• National Institute on Drug Abuse. Research Report Series: Methamphetamine (NIH Publication No. 13-4210). National Institutes of Health. Accessed March 18, 2019.
• Ernst, T.; Chang, L.; Leonido-Lee, M.; and Speck, O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54(6):1344-1349, 2000.
• D. Vearrier, M.I. Greenberg, S.N. Miller, J.T. Okaneku, D.A. Haggerty Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine
• NIDA Research Report
• Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
• Substance Abuse and Mental Health Services Administration (SAMHSA). Office of Applied Studies
• Scott, J.C., Woods, S.P., Matt, G.E. et al. Neuropsychol Rev (2007) 17: 275. https://doi.org/10.1007/s11065-007-9031-0 https://www.ncbi.nlm.nih.gov/pubmed/17694436/
• Ernst, T.; Chang, L.; Leonido-Lee, M.; and Speck, O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54(6):1344-1349, 2000.
• Klasser GD, Epstein J. Methamphetamine and its impact on dental care. J Can Dent Assoc 2005;71(10):759-62.
• De-Carolis, C; Boyd, GA; Mancinelli, L; Pagano, S; Eramo, S (1 March 2015). “Methamphetamine abuse and “meth mouth” in Europe” (PDF). Medicina oral, patologia oral y cirugia bucal. 20 (2): e205–10. PMC 4393984. PMID 25662544.
• DSM-IV-TR (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association.
• Lago JA, Kosten TR (1994) Stimulant withdrawal. Addiction 89: 1477-1481.
• Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, et al. (2010) Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 105: 1809-1818.
• McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, et al. (2005) The nature, time course and severity of methamphetamine withdrawal. Addiction 100: 1320-1329.
• C. D’Arcy, J.E. Luevano, M. Miranda-Arango, J.A. Pipkin, J.A. Jackson, E. Castaneda, et al.Extended access to methamphetamine self-administration up-regulates dopamine transporter levels 72 hours after withdrawal in rats Behav Brain Res, 296 (2016), pp. 125-128
• F. Chiadmi, J. Schlatter[Crystal meth: a particular form of methamphetamine] Presse Med, 38 (2009), pp. 63-67
• M.E. Nelson, S.M. Bryant, S.E. AksEmerging drugs of abuse Emerg Med Clin North Am, 32 (2014), pp. 1-28
• https://www.healthline.com/health/addiction#support
• Roll JM, Petry NM, Stitzer ML, et al. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry 2006;163:1993-9.
• Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev 2001;(4):CD003022.
• Rawson RA, Marinelli-Casey P, Anglin MD, et al. A Multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004;99:708-17.
• NIDA. (2019, October 16). Methamphetamine. Retrieved from https://www.drugabuse.gov/publicarions/research-reports/methamphetamine on 2019, November 25.
• United Nations Office on Drugs and Crime, 2007, https://www.unodc.org/pdf/research/wdr07/WDR_2007.pdf
• Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206-1214.
• Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Yoshikawa E, Futatsubashi M, Mori N (2003) Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortex with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160: 1699-1701
• Yen DJ, Wang SJ, Chen CC, Liao KK, Fuh JL, Hu HH (1994) Stroke associated with methamphetamine inhalation. Eur Neurol 34: 16-22.
• Perez JA, Arsura EL, Strategos S (1999) Methamphetamine-related stroke: four cases. J Emerg Med 17: 469-471
• Kao CH, Wang SJ, Yeh SH (1994) Presentation of regional cerebral blood flow in amphetamine abusers by 99Tcm-HMPAO brain SPECT. Nucl Med Commun 15: 94-98.
• Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54: 1344-1349.
• Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
• London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Kurian V, Newton T, Woods RP, Rawson R, Ling W (2004) Regional cerebral dysfunction associated with mood disturbances in abstinent methamphetamine abusers. Arch Gen Psychiatry 61: 73-84.
• Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206-1214
• Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
• Iyo M, Namba H, Yanagisawa M, Hirai S, Yui N, Fukui S (1997) Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT. Prog Neuropsychopharmacol Biol Psychiatry 21: 789-796.